Edition:
United Kingdom

People: CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

11.44HKD
14 Jun 2019
Change (% chg)

HK$-0.12 (-1.04%)
Prev Close
HK$11.56
Open
HK$11.62
Day's High
HK$11.62
Day's Low
HK$11.30
Volume
22,799,050
Avg. Vol
33,754,105
52-wk High
HK$25.20
52-wk Low
HK$9.90

Li, Chunlei 

Mr. Li Chunlei is Executive Director of the Company. Mr. Li is currently the Chief Scientist of the Group in charge of research and development. Mr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Mr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Mr. Li is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of approximately 20 nano drugs including “Duomeisu” (doxorubicin hydrochloride liposome injection) and paclitaxel albumin-bound nano particles.

Basic Compensation

Total Annual Compensation, HKD 119,000
Restricted Stock Award, HKD --
Long-Term Incentive Plans, HKD --
All Other, HKD 3,000
Fiscal Year Total, HKD 122,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Dongchen Cai

13,328,000

Cuilong Zhang

--

Kin Man Chak

5,045,000

Chunlei Li

122,000

Hua Lu

4,208,000

Weidong Pan

4,733,000
As Of  31 Dec 2017